Targeted therapy in BRAF-mutated lung adenocarcinoma

Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle, Youssouf Oulkhouir, Martin Schuler, Alessandra Curioni-Fontecedro, Benjamin Huret, Mallorie Kerjouan, Sebastian Michels, Georg Pall, Sacha Rothschild, Gerald Schmid-Bindert, Matthias Scheffler, Rémi Veillon, Luciano Wannesson, Joachim Diebold, Gérard Zalcman, Thomas Filleron, Julien Mazières, None, Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Journal of Thoracic Oncology. ,vol. 10, pp. 1451- 1457 ,(2015) , 10.1097/JTO.0000000000000625

David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S. Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoine Italiano, Ralf-Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schuler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzen, Maria Luisa Veronese, Josep Tabernero, José Baselga, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations The New England Journal of Medicine. ,vol. 373, pp. 726- 736 ,(2015) , 10.1056/NEJMOA1502309

Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion-Sileni, Kamil Drucis, Ivana Krajsova, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V Long, Keith Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D Rubin, Shonda M Little, Dirk Schadendorf, None, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib The New England Journal of Medicine. ,vol. 372, pp. 30- 39 ,(2015) , 10.1056/NEJMOA1412690

Monika Joshi, Shawn J. Rice, Xin Liu, Bruce Miller, Chandra P. Belani, Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer PLOS ONE. ,vol. 10, pp. e0118210- ,(2015) , 10.1371/JOURNAL.PONE.0118210

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella-Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles Rudin, Joan Schiller, Eric B. Haura, Mark Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn, Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs JAMA. ,vol. 311, pp. 1998- 2006 ,(2014) , 10.1001/JAMA.2014.3741

Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Celeste Lebbe, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven J. O'Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur, Paul B. Chapman, Axel Hauschild, Caroline Robert, John B. Haanen, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation The New England Journal of Medicine. ,vol. 364, pp. 2507- 2516 ,(2011) , 10.1056/NEJMOA1103782

Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo De Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob, Vanna Chiarion-Sileni, Celeste Lebbe, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John BAG Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Nadezhda Kovalenko, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J DeMarini, Jhangir G Irani, Suzanne Swann, Jeffrey J Legos, Fan Jin, Bijoyesh Mookerjee, Keith Flaherty, None, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial The Lancet. ,vol. 386, pp. 444- 451 ,(2015) , 10.1016/S0140-6736(15)60898-4

Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen, Salvador Martín-Algarra, Boguslawa Karaszewska, Cornelia Mauch, Vanna Chiarion-Sileni, Anne-Marie Martin, Suzanne Swann, Patricia Haney, Beloo Mirakhur, Mary E Guckert, Vicki Goodman, Paul B Chapman, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial The Lancet. ,vol. 380, pp. 358- 365 ,(2012) , 10.1016/S0140-6736(12)60868-X

David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly, B C Cho, Mark A Socinski, Lini Pandite, Christine Nase, Bo Ma, Anthony D'Amelio, Bijoyesh Mookerjee, C Martin Curtis, Bruce E Johnson, Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncology. ,vol. 17, pp. 642- 650 ,(2016) , 10.1016/S1470-2045(16)00077-2

David Planchard, Harry J.M. Groen, Tae Min Kim, James R. Rigas, Pierre Jean Souquet, Christina S. Baik, Fabrice Barlesi, Julien Mazières, Elisabeth A. Quoix, C. Martin Curtis, Bijoyesh Mookerjee, Arundathy N. Bartlett-Pandite, Christine Tucker, Anthony D'Amelio, Bruce E. Johnson, Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 33, pp. 8006- 8006 ,(2015) , 10.1200/JCO.2015.33.15_SUPPL.8006